Postmarketing surveillance study of asciminib in patients with resistant/intolerant chronic myeloid leukemia in Japan.
Saved in:
| Title: | Postmarketing surveillance study of asciminib in patients with resistant/intolerant chronic myeloid leukemia in Japan. |
|---|---|
| Authors: | Yamaguchi K; Clinical Development Japan CDD 3, Novartis Pharma K.K., Toranomon Hills Mori Tower, 23-1, Toranomon 1-Chome, Minato-ku, Tokyo, 105-6333, Japan. kazuaki.yamaguchi@novartis.com., Aoki M; Clinical Development Japan CDD 3, Novartis Pharma K.K., Toranomon Hills Mori Tower, 23-1, Toranomon 1-Chome, Minato-ku, Tokyo, 105-6333, Japan., Osako R; Clinical Development Japan CDD 3, Novartis Pharma K.K., Toranomon Hills Mori Tower, 23-1, Toranomon 1-Chome, Minato-ku, Tokyo, 105-6333, Japan. |
| Source: | International journal of hematology [Int J Hematol] 2026 Mar 31. Date of Electronic Publication: 2026 Mar 31. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Springer Japan Country of Publication: Japan NLM ID: 9111627 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1865-3774 (Electronic) Linking ISSN: 09255710 NLM ISO Abbreviation: Int J Hematol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 41917309 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Postmarketing surveillance study of asciminib in patients with resistant/intolerant chronic myeloid leukemia in Japan. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Yamaguchi+K%22">Yamaguchi K</searchLink>; Clinical Development Japan CDD 3, Novartis Pharma K.K., Toranomon Hills Mori Tower, 23-1, Toranomon 1-Chome, Minato-ku, Tokyo, 105-6333, Japan. kazuaki.yamaguchi@novartis.com.<br /><searchLink fieldCode="AU" term="%22Aoki+M%22">Aoki M</searchLink>; Clinical Development Japan CDD 3, Novartis Pharma K.K., Toranomon Hills Mori Tower, 23-1, Toranomon 1-Chome, Minato-ku, Tokyo, 105-6333, Japan.<br /><searchLink fieldCode="AU" term="%22Osako+R%22">Osako R</searchLink>; Clinical Development Japan CDD 3, Novartis Pharma K.K., Toranomon Hills Mori Tower, 23-1, Toranomon 1-Chome, Minato-ku, Tokyo, 105-6333, Japan. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%229111627%22">International journal of hematology</searchLink> [Int J Hematol] 2026 Mar 31. <i>Date of Electronic Publication: </i>2026 Mar 31. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer+Japan%22">Springer Japan </searchLink><i>Country of Publication: </i>Japan <i>NLM ID: </i>9111627 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1865-3774 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2209255710%22">09255710 </searchLink><i>NLM ISO Abbreviation: </i>Int J Hematol <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41917309 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1007/s12185-026-04199-x Languages: – Code: eng Text: English Titles: – TitleFull: Postmarketing surveillance study of asciminib in patients with resistant/intolerant chronic myeloid leukemia in Japan. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Yamaguchi K – PersonEntity: Name: NameFull: Aoki M – PersonEntity: Name: NameFull: Osako R IsPartOfRelationships: – BibEntity: Dates: – D: 31 M: 03 Text: 2026 Mar 31 Type: published Y: 2026 Identifiers: – Type: issn-electronic Value: 1865-3774 Titles: – TitleFull: International journal of hematology Type: main |
| ResultId | 1 |
